Journal
MOLECULAR THERAPY
Volume 26, Issue 4, Pages 1082-1092Publisher
CELL PRESS
DOI: 10.1016/j.ymthe.2018.02.008
Keywords
-
Categories
Funding
- Agence Nationale de la Recherche under the frame program Investissements d'Avenir [ANR-10-IDEX-0002-02, ANR-14-CE12-0009]
- Myotubular Trust
- Sparks the Children's Medical Research Charity
- Association Francaise contre les Myopathies [AFM 20323]
- SATT Alsace Conectus
- MRT fellowship
- [ANR-10-LABX-0030-INRT]
- Sparks Charity [14IGB01] Funding Source: researchfish
Ask authors/readers for more resources
Myotubular myopathy, or X-linked centronuclear myopathy, is a severe muscle disorder representing a significant burden for patients and their families. It is clinically characterized by neonatal and severe muscle weakness and atrophy. Mutations in the myotubularin (MTM1) gene cause myotubular myopathy, and no specific curative treatment is available. We previously found that dynamin 2 (DNM2) is upregulated in both Mtm1 knockout and patient muscle samples, whereas its reduction through antisense oligonucleotides rescues the clinical and histopathological features of this myopathy in mice. Here, we propose a novel approach targeting Dnm2 mRNA. We screened and validated in vitro and in vivo several short hairpin RNA (shRNA) sequences that efficiently target Dnm2 mRNA. A single intramuscular injection of AAV-shDnm2 resulted in long-term reduction of DNM2 protein level and restored muscle force, mass, histology, and myofiber ultrastructure and prevented molecular defects linked to the disease. Our results demonstrate a robust DNM2 knockdown and provide an alternative strategy based on reduction of DNM2 to treat myotubular myopathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available